Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) reported Q1 EPS of ($0.85), $0.48 worse than the analyst estimate of ($0.37).

For earnings history and earnings-related data on Ultragenyx Pharmaceutical Inc. (RARE) click here.